Lindahl assisted Newbury Pharmaceuticals AB with listing of the company's shares on Nasdaq First North Growth Market. In connection with the listing, a new share issue of approximately SEK 50 million was carried out for the general public in Sweden, Norway, Denmark and Finland as well as for institutional investors. There was a great deal of interest in the offer, which was oversubscribed. The first day of trading is 4 February.
Newbury provides prescription medicines to patients and healthcare providers in the Scandinavian market. The company focuses on speciality medicines and proprietary brands with particular focus on oncology, rare diseases and neurology.
Lindahl acted as legal advisor to Newbury in connection with the listing and raising capital and the team consisted mainly of Johan Herrström and Pontus Söderberg.
